Bivictrix Therapeutics PLC on Wednesday said it has been granted a US patent for lead asset BVX001.
The Macclesfield, England-based biotechnology company focusing on cancer therapies said the patent, granted by the US Patent & Trademark Office, ‘provides ultimate broad protection’ for the antibody drug conjugate therapy which targets leukaemia.
On Wednesday, Bivictrix also noted that it expects to be granted a patent from the Japanese Patent Office in the coming weeks. It is currently seeking patent approval in seven countries.
Chief Executive Officer Tiffany Thorn said: ‘This patent grant is expected to be the first of many as we continue to prosecute the wider patent family in seven further jurisdictions worldwide, creating a robust patent protected portfolio.’
Shares in Bivictrix were up 1.5% at 13.20 pence each in London on Wednesday morning.
Copyright 2023 Alliance News Ltd. All Rights Reserved.
